IAP6 Rec'd PCT/PTO 09 APR 2007

PATENT ATTORNEÝ DOCKET NO. 50026/059001

Certificate of Mailing: Date of Deposit: April 5, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Collette R. D'Amico

Printed name of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Iwadate et al.

Confirmation No.: 4667

Serial No.:

10/585,884

Art Unit:

Not yet assigned

Filed:

July 12, 2006

Examiner:

Not yet assigned

Customer No.:

21559

Title:

GENE THERAPY FOR TUMORS USING MINUS-STRAND RNA

VIRAL VECTORS ENCODING IMMUNOSTIMULATORY

CYTOKINES (AS AMENDED)

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made. nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office Action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 5 April 2007

James D. DeCamp, Ph.D.

Reg. No. 43,580

JAN N. TITTEZ, Ph.D. Peg. No. 52,290

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

| SUBSTITUTE FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50026/059001 |
|---|--|---------------------|------------------|
| (MODIFIED) | | Serial No. | 10/585,884 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant | lwadate et al. |
| | | Filing Date | July 12, 2006 |
| | | Group | Not yet assigned |
| (37 C.F.R. § 1.98(b)) | | IDS Filed | April 5, 2007 |

| U.S. PATENT DOCUMENTS | | | | |
|------------------------|--------------------|---------------------|-----------------------|--|
| Examiner's Initials | Document Number | Publication Date | Patentee or Applicant | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| | FOREIGI | N PATENT OR PUBLISHED | FOREIGN PATENT APPLICATION | |
|------------------------|--------------------|-----------------------|-----------------------------|----------------------|
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Translation (Yes/No) |
| | WO 01/04271 A2 | January 18, 2001 | | |
| | | | | |
| | | | | |

| Ext | ue et al., "A New Sendai Virus Vector Deficient in the Matrix Gene Does Not Form Virus Particles and Shows ensive Cell-to-Cell Spreading," <i>Journal of Virology</i> 77(11):6419-6429 (2003). |
|-------------|--|
| lwa thro | date et al., "Recombinant Sendai Virus Vector Induces Complete Remission of Established Brain Tumors |
| | bugh Efficient Interleukin-2 Gene Transfer in Vaccinated Rats," Clin. Cancer Res. 11(10):3821-3827 (2005). |
| Ma US | rkwell et al., "Specific Gangliosides Function as Host Cell Receptors for Sendai Virus," <i>Proc. Natl. Acad. Sci.</i> A 78(9):5406-5410 (1981). |
| Sur | oplemental European Search Report for EP 05 70 3477, March 1, 2007. |

| EXAMINER | DATE CONSIDERED | |
|---|-----------------|--|
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | | |